๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangzhou

3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial
NCT06974968Spinal Cord Injury, Safety, Efficacy, Clinical Trial
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Phase 2
60
Guangzhou
2028-05-25
Not yet open
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
NCT07382375Aortic Aneurysm and Dissection
Nanjing Medical University
Not applicable
300
Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, Shanghai
2027-12-31
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Beijing, Chongqing, Guangzhou, Guiyang, Harbin, Wuhan, Changsha, Nanjing
2027-11-23
Recruiting
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
NCT06902012Relapsed/Refractory Diffuse Large B-cell Lymphoma
Zhujiang Hospital
Phase 1/2
15
Guangzhou
2027-02
Not yet open
TEER In dynaMic sEvere Functional Mitral Regurgitation (TIMER)
NCT07197021Mitral Regurgitation Functional
Sun Yat-sen University
Not applicable
540
Guangzhou
2027-01-01
Not yet open
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
NCT07686796Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT
Guangdong Provincial People's Hospital
Phase 3
148
Guangzhou
2027-01-01
Not yet open
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
NCT06136507Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
76
Chongqing, Guangzhou, Guizhou, Hangzhou, Hefei, Nanjing, Qingdao, Shenzhen
2026-12-25
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
2,380
Hefei, Beijing, Shenzhen, Guangzhou, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2026-12-16
Not yet open
Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency
NCT07786571Type 2 Diabetes Mellitus (T2DM), Chronic Renal Insufficiency, Chronic Kidney Disease (Stages 3b-5), Glucose Homeostasis
Sun Yat-sen University
Not applicable
206
Guangzhou
2026-12-01
Not yet open
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861Obesity, Overweight
Eli Lilly and Company
Phase 3
192
Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang
2026-12
Not yet open
Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer
NCT07714447CRC (Colorectal Cancer), BRAF
Sun Yat-sen University
Phase 2
91
Guangzhou
2026-11-30
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
Boehringer Ingelheim
Phase 3
270
Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing
2026-11-09
Not yet open
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
NCT07255612Breast Cancer
Sun Yat-sen University
Phase 2
29
Guangzhou
2026-11-04
Not yet open
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606Platinum-sensitive Recurrent Ovarian Cancer
Hansoh BioMedical R&D Company
Phase 3
460
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shaoguan, Nanning, Harbin
2026-11-01
Not yet open
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
NCT07725484Heart Failure Due to Coronary Artery Disease
Shanghai Zhongshan Hospital
Phase 3
1,526
Hefei, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Nanjing, Dalian, Xi'an
2026-11-01
Not yet open
A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
NCT07816237Paroxysmal Nocturnal Hemoglobinuria, PNH
Bisirna Therapeutics (Suzhou) Co., Ltd.
Phase 3
70
Beijing, Jilin City, Quanzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2026-10-29
Not yet open
A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
NCT07754786Atopic Dermatitis
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
520
Guangzhou
2026-10-20
Not yet open
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma
NCT07827872Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer
caohaotian
Phase 3
300
Guangzhou
2026-10-01
Not yet open
Efficacy Analysis of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Tailor-Made Notched Music Therapy in the Treatment of Chronic Subjective Tinnitus
NCT07794462Chronic Subjective Tinnitus
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
444
Guangzhou, Huizhou, Jieyang, Zhongshan, Zhuhai, Shanghai
2026-10-01
Not yet open
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
NCT07819591SCLC, Recurrent
Shaodong Hong
Phase 2
47
Guangzhou
2026-10-01
Not yet open
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
NCT07789184Gastric Cancer, Peritoneal Metastasis
Hua Huang, MD, PhD
Phase 3
170
Beijing, Chongqing, Zhangzhou, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang
2026-10-01
Not yet open
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
NCT07784101Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
280
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2026-10
Not yet open
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
NCT07824856Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
Sun Yat-sen University
Phase 2
138
Guangzhou
2026-10
Not yet open
Safety Study of GMDTC Injection in Participants With Solid Tumors and Cisplatin-Induced Renal Dysfunction
NCT07824843Cisplatin Nephrotoxicity, Cisplatin Adverse Reaction
Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.
Phase 1
60
Guangzhou
2026-10
Not yet open
A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anfluยฎ) Pregnant Women (AnFLU-PREG)
NCT07832201Influenza
Sinovac Biotech Co., Ltd
Phase 4
150
Changsha, Chengdu, Chongqing, Guangzhou, Nanjing, Wuhan
2026-10
Not yet open
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
NCT07828353COPD (Chronic Obstructive Pulmonary Disease)
Regend Therapeutics
Phase 3
102
Guangzhou
2026-10
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Dongguan Shi, Guangzhou, Jiangmen, Zhongshan, Guilin
2026-09-30
Not yet open
Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial
NCT07767552Diabetes Mellitus, Type 2
Yanbing Li
Not applicable
249
Guangzhou
2026-09-30
Not yet open
Trastuzumab Rezetecan and Carboplatin ยฑ Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
NCT07776171Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)
Sun Yat-sen University
Phase 2
176
Guangzhou
2026-09-30
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
AstraZeneca
Phase 3
600
Beijing, Guangdong Province, Guangzhou, Wuhan
2026-09-29
Not yet open
A Study of Full-Spectrum Screen Lighting for Reducing Screen-Related Eye Fatigue and Dry Eye
NCT07706231Visual Fatigue, Dry Eye, Computer Vision Syndrome
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
112
Guangzhou
2026-09-22
Not yet open
Renal Oxygenation-Guided AKI Reduction Trial
NCT07816640Acute Kidney Injury, Hepatectomy
Chinese PLA General Hospital
Not applicable
1,200
Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2026-09-20
Not yet open
Research on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models
NCT07767565Breast Cancer, Exercise and Recovery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
40
Guangzhou
2026-09-15
Not yet open
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
NCT07632235Intrahepatic Cholangiocarcinoma (Icc)
Shanghai 6th People's Hospital
Phase 1/2
112
Guangzhou, Shanghai, Wuhan
2026-09-15
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704Arthritis, Rheumatoid
Bristol-Myers Squibb
Phase 1/2
84
Beijing, Guangzhou, Zhengzhou, Nanchang, Shanghai
2026-09-15
Not yet open
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
466
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou
2026-09-14
Recruiting
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive๏ผŒ Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
NCT07796880Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma, Early-Stage Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
80
Guangzhou
2026-09-14
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
Vividion Therapeutics, Inc.
Phase 2
140
Bengbu, Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Jinan, Shanghai
2026-09-11
Not yet open
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188Lupus Nephritis
Zhao Minghui
Phase 3
70
Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai
2026-09-10
Not yet open
Effects of Different PICC Catheterization Methods: A Multicenter Randomized Controlled Trial
NCT07791719Cancer Patients
Sun Yat-sen University
Not applicable
801
Guangzhou
2026-09-10
Recruiting
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459Idiopathic Pulmonary Fibrosis
InSilico Medicine Hong Kong Limited
Phase 3
320
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Haikou, Shijiazhuang
2026-09-09
Not yet open
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
NCT07791758Metastatic Colorectal Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
369
Guangzhou, Guilin, Nanning, Luoyang, Nanchang, Jinan, Shanghai, Chengdu
2026-09-04
Not yet open
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
NCT07751848Lupus Erythematosus, Systemic
AstraZeneca
Phase 3
417
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangdong Province, Guangzhou, Hangzhou
2026-09-04
Not yet open
Sphere-9 PAF China Study
NCT07789925Paroxysmal Atrial Fibrillation (PAF)
Medtronic Cardiac Ablation Solutions
Not applicable
180
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin
2026-09-02
Recruiting
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
NCT07724366Psoriasis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
400
Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Haikou, Chengde
2026-09-02
Not yet open
Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia
NCT07735104Cancer Cachexia Syndrome, Cancer Cachexia
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
88
Guangzhou
2026-09-01
Not yet open
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
NCT07756190Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
28
Guangzhou
2026-09-01
Not yet open
Study of SG301 for Renal AMR After Transplantation
NCT07764627Antibody Mediated Rejection
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
10
Guangzhou, Nanning, Zhengzhou, Changsha, Jinan, Chengdu, Hangzhou
2026-09-01
Not yet open
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited
Phase 3
380
Bengbu, Hefei, Beijing, Chongqi, Fuzhou, Lanzhou, Wuwei, Guangzhou
2026-09-01
Not yet open
Clinical and Subclinical Keratoconus Cohort Study
NCT07553832Keratoconus
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
421
Guangzhou
2026-09-01
Not yet open
Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
NCT07550855Follicular Lymphoma (FL)
Sun Yat-sen University
Phase 2
52
Guangzhou
2026-09-01
Not yet open
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
NCT07831395Richter Syndrome
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
23
Zhengzhou, Changsha, Nanchang, Guangzhou, Nanjing, Wuhan
2026-09-01
Not yet open
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
NCT07766889Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
32
Guangzhou
2026-09-01
Not yet open
Cross-Regional Unmanned Aircraft Transport of Donor Lungs
NCT07790822Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Disease (ILD), End-stage Lung Disease
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
25
Guangzhou
2026-09-01
Not yet open
Self-Management Support for Acute Coronary Syndrome Patients After Hospital Discharge
NCT07799376Acute Coronary Syndrome (ACS)
Nanfang Hospital, Southern Medical University
Not applicable
80
Guangzhou
2026-09-01
Not yet open
Clinical Efficacy Study of Magnesium-Containing Degradable Polymer Bone Repair Material for Bone-Defect Repair After Extremity Bone Tumor Resection
NCT07794202Bone Defect, Bone Tumor of Extremity, Bone-Like Tumor Lesion
Yu Zhang, PhD
Not applicable
72
Guangzhou
2026-09-01
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
NCT07796516Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis
Peking University People's Hospital
Phase 2
420
Hefei, Beijing, Chongqing, Quanzhou, Guangzhou, Jiangmen, Shenzhen, Nanning
2026-09-01
Not yet open
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC
NCT07765667Rectal Adenocarcinoma, High-Risk Cancer, MSS
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
100
Guangzhou
2026-09-01
Not yet open
Terbinafine for CSA-AKI Prevention
NCT07738328Acute Kidney Injury, Cardiac Surgical Procedures
Guangdong Provincial People's Hospital
Phase 2
208
Guangzhou
2026-09-01
Not yet open
Effect of a Standardized Oral Care Program on Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial(SOC-HSCT)
NCT07809451Oral Mucositis, Hematopoietic Stem Cell Transplantation (HSCT)
Nanfang Hospital, Southern Medical University
Not applicable
126
Guangzhou
2026-09-01
Not yet open
Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial
NCT07774754Rectal Cancer
Sun Yat-sen University
Phase 2
18
Guangzhou
2026-09-01
By invitation
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
NCT07813390Acute Myeloid Leukemia (AML)
Guangdong Second Provincial General Hospital
Phase 2
73
Guangzhou
2026-09-01
Not yet open
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
Antengene Biologics Limited
Phase 1
149
Bengbu, Hefei, Beijing, Xiamen, Guangzhou, Luoyang, Zhengzhou, Wuhan
2026-09-01
Not yet open
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
NCT07783321Nasopharyngeal Carcinoma (NPC)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
404
Guangzhou
2026-09
Not yet open
JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT07797153Recurrent or Metastatic Cervical Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
368
Guangzhou, Shanghai
2026-09
Not yet open
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
NCT07797881Nasopharyngeal Carcinoma (NPC)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
60
Guangzhou
2026-09
Not yet open
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
NCT07750704ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
153
Guangzhou
2026-09
Not yet open
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07827261Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
36
Guangzhou
2026-09
Not yet open
A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention
NCT07798284Overweight/Obesity
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
80
Beijing, Guangzhou, Zhengzhou, Wuhan, Xianning, Jinan, Shanghai, Luzhou
2026-09
Recruiting
Plantar Stimulation, Whole-Body Vibration, and Baduanjin for Muscle Activation
NCT07811674Flat Feet, Lower-Limb Muscle Activation, Neuromuscular Response
Nanfang Hospital, Southern Medical University
Not applicable
30
Guangzhou
2026-09
Not yet open
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
NCT07678593Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
222
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Xi'an, Jinan
2026-09
Not yet open
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
NCT07767253Dermatitis, Atopic
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
246
Beijing, Guangzhou, Changsha, Hangzhou
2026-09
Not yet open
A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
NCT07757230Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2
87
Guangzhou
2026-09
Not yet open
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
NCT07803471Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Coronary Heart Disease (CHD)
China Academy of Chinese Medical Sciences
Not applicable
100
Guangzhou, Zhengzhou, Jinan, Tianjin
2026-09
Not yet open
Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature
NCT07815626Idiopathic Short Stature (ISS)
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase 3
240
Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing
2026-09
Not yet open
Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
NCT07769658Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Observational
500
Guangzhou, Zhengzhou, Shanghai, Chengdu, Tianjin, Kunming
2026-09
Not yet open
Guided Laminectomy With Augmented Duroplasty for Acute Traumatic Spinal Cord Injury
NCT07733401Spinal Cord Injury, Acute Spinal Cord Injury (SCI)
Xuanwu Hospital, Beijing
Not applicable
80
Beijing, Guangzhou, Maoming, Cangzhou, Shijiazhuang, Chifeng, Dezhou, Jinan
2026-09
Not yet open
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
NCT07818499Diffuse Large B-Cell Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
204
Guangzhou, Suzhou
2026-09
Not yet open
Percutaneous Pulsed Electric Field Ablation for Early-Stage NSCLC and Lung Oligometastases: A Safety and Efficacy Study
NCT07799194Lung Cancer (NSCLC)
Energenx Medical LTD.
Not applicable
10
Guangzhou
2026-09
Not yet open
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
NCT07818486Nasopharyngeal Carcinoma (NPC), Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
30
Chongqing, Guangzhou
2026-09
Recruiting
SKB565 for Injection in Advanced Solid Tumors
NCT07545265Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
180
Guangzhou
2026-08-31
Not yet open
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07701681ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University
Phase 2
75
Guangzhou
2026-08-31
Not yet open
A Phase 2 Study of ABSK043 Combined With Osimertinib
NCT07710612Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Abbisko Therapeutics Co, Ltd
Phase 2
72
Guangzhou, Harbin, Wuhan, Shenyang, Shanghai, Taiyuan, Hangzhou
2026-08-31
Not yet open
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
NCT06970496Relapsed or Refractory B Cell Non Hodgkin Lymphoma
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
48
Guangzhou, Nanchang, Shanghai, Wenzhou, Xi'an
2026-08-31
Not yet open
Efficacy and Safety of Anrikefon Injection for Multimodal Postoperative Analgesia in Patients Undergoing Laparoscopic Hepatectomy
NCT07801183Postoperative Acute Pain
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4
117
Guangzhou
2026-08-30
Recruiting
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
NCT07796789Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
204
Guangzhou, Changsha, Fuzhou
2026-08-30
Recruiting
A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism
NCT06819865Acute Pulmonary Embolism
Boston Scientific Corporation
Observational
30
Guangzhou
2026-08-30
Not yet open
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
NCT07745257HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Sun Yat-sen University
Phase 2
40
Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu
2026-08-28
Recruiting
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
NCT07412262Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
32
Guangzhou, Wuhan
2026-08-28
Recruiting
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
NCT07819656Nasopharyngeal Carcinoma (NPC), Myelosuppression
Nanfang Hospital, Southern Medical University
Observational
1,782
Guangzhou
2026-08-26
Recruiting
A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer
NCT07735377Prostate Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
118
Guangzhou
2026-08-26
Recruiting
A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
NCT07730190Advanced Malignancies
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
145
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai
2026-08-25
Recruiting
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
NCT07747857Type 2 Diabetes Mellitus Combined With Overweight or Obesity
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
72
Fuzhou, Guangzhou, Langfang, Luoyang, Wuhan, Yichang, Changsha, Nanjing
2026-08-25
Recruiting
A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
NCT07726992Papillary-Only Non-muscle-invasive Bladder Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
750
Beijing, Guangzhou
2026-08-25
Recruiting
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07779252Moderate to Severe Glabellar Lines
Ipsen
Phase 3
160
Guangzhou, Changsha, Nanjing, Wuxi, Jingโ€™an, Chengdu, Hangzhou, Beijing
2026-08-25
Not yet open
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
NCT07683806Seborrheic Dermatitis
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
309
Bengbu, Wuhu, Fuzhou, Xiamen, Guangzhou, Shenzhen, Haikou, Baoding
2026-08-24
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
500
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo
2026-08-24
Not yet open
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
NCT07720193Advanced Extrapulmonary Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 3
280
Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Harbin, Luoyang, Zhengzhou
2026-08-22
Not yet open
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
1,500
Beijing, Cangzhou, Changchun, Chengdu, Danyang, Ganzhou, Guangzhou, Huizhou
2026-08-21
Not yet open
VIPeerAgent for Adolescent Mental Health
NCT07778758Youth Mental Health, Psychological Distress in Adolescents and Young Adults, Early Intervention
Sun Yat-sen University
Not applicable
234
Guangzhou
2026-08-20
Rows per page Showing 1–100 of 3318
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,318 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,972 of the 3,318 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 473 have not yet opened recruitment, 805 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 3,318 studies
PhaseStudiesRecruitingShare
Phase 391445027.5%
Phase 272341721.8%
Observational51135015.4%
Not applicable44527313.4%
Phase 12541797.7%
Phase 1/22541847.7%
Phase 2/398593%
Phase 497502.9%
Phase EARLY_PHASE122100.7%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Sun Yat-sen University451276
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181113
Nanfang Hospital, Southern Medical University13892
AstraZeneca13359
Guangdong Provincial People's Hospital8147
Sixth Affiliated Hospital, Sun Yat-sen University7354
Merck Sharp & Dohme LLC6330
Janssen Research & Development, LLC6028
Hoffmann-La Roche5521
Novartis Pharmaceuticals5423
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.